Market news

Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...

On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYL

Scott L Burrows, Chief Financial Officer, on September 01, 2026, sold 25,732 shares in Spyre Therape

Heidy King-Jones, Chief Legal Officer and Corporate Secretary, on September 01, 2026, sold 28,399 sh

Cameron Turtle, Director, Chief Executive Officer, on September 01, 2026, sold 15,000 shares in Spyr

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event: Citi 2026 BioPharma Back to School Conference – New YorkDate:

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) fell 13% to $94 on August 26, 2026, but the sell-off sharply overreacted to the underlying data. The company’s SPY072 asset, tested in a rheumatoid arthritis sub-study of the Phase 2 SKYWAY trial reported August 25, cleared statistical significance versus placebo on one or more of the primary DAS28-CRP endpoints and […]

Shares of Spyre Therapeutics (SYRE) declined this week after the company reported topline results of its TL1A antibody SPY072 from the SKYWAY trial’s...

Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) SPY072 was well tolerated with rates of adverse events comparable to placebo Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoim

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum. Shares are trading at a new 3-year high. SYRE maintains a 100% “Buy” technical opinion from Barchart. Short interest is elevated at 13.81% of...

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

Spyre Therapeutics has delivered a very strong 3 year return while its current valuation checks suggest the stock is not cheap, which raises questions about how much of the recent optimism is already in the price. The stock has returned roughly 7x over the past 3 years, which is an unusually large move that can leave new buyers with less room for error if expectations cool. Positive Phase 2 data across key ulcerative colitis programs can support higher growth expectations, but the reliance...

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in...

This disposition follows a staggering 500% one-year stock surge.

This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months.

This disposition follows a staggering 500% one-year stock surge.

This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months.

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.